FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and may be used for treating Philadelphia chromosome positive leukaemia (Ph+ leukaemia). A method of treating chronic myeloid leukaemia (CML) or Philadelphia chromosome positive acute lymphoblast leukaemia (Ph+ALL) in a group of human patients involves the stages as follows: (a) introducing the pre-determined fixed amount of imanitib or a pharmaceutically acceptable salt thereof in human patients in need thereof, (b) selecting at least one blood sample in the specified patients for at least first three months of the therapy, (c) determining minimal plasma imanitib (Cmin), and (d) specifying a dose of imanitib or the pharmaceutically acceptable salt thereof so that Cmin falling within the range of 1000 ng/ml and 3000 ng/ml is achieved in each patient wherein threshold Cmin 1000 ng/ml has not been achieved before specifying the dose. The group of inventions also involves the use of imanitib or the pharmaceutically acceptable salt thereof for preparing a medicine for treating Ph+ leukaemia.
EFFECT: group of inventions enables minimising or avoiding the formation of resistance, loss of effectiveness and a risk of recurrence in human patients suffering CML or Ph+ALL and treated with imanitib or the pharmaceutically acceptable salt thereof.
14 cl, 8 dwg, 2 tbl, 2 ex
